Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Autacoids and Related Drugs Technologies and Global Markets |
Apr 2010 | £3,065 | 100% |
| NicOx SA – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 92% |
| Pain Therapeutics Technologies, Markets and Companies |
Jan 2012 | £2,590 | 89% |
| Alzheimer's disease Technologies, Markets and Companies |
Jan 2012 | £2,265 | 87% |
| Nitromed, Inc Premium Company Profile |
Dec 2007 | £170 | 86% |
| Neuroprotection (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,240 | 85% |
| 21st European Meeting on Hypertension and Cardiovascular Prevention 2011 Post-Conference Review and Analysis |
Jun 2011 | £630 | 83% |
| Pulmonary Embolism - Pipeline Review H2 2011 |
Aug 2011 | £315 | 81% |
| Shock - Pipeline Review H2 2011 |
Nov 2011 | £315 | 80% |
| Dermatomycoses - Pipeline Review H2 2011 |
Nov 2011 | £315 | 80% |
| Market for Medical Inhalants | Nov 2010 | £93 | 78% |
| Athlete's Foot (Tinea Pedis) - Pipeline Review H2 2011 |
Aug 2011 | £315 | 76% |
| Septic Shock - Pipeline Review H2 2011 |
Aug 2011 | £315 | 76% |
| Biomarkers (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,240 | 73% |
| Cardiovascular Drug Delivery Technologies, Markets and Companies |
Jan 2012 | £1,815 | 67% |
| Staphylococcus Aureus Infections - Pipeline Review Q2 2011 |
May 2011 | £315 | 65% |
| Migraine Therapeutics Pipeline Assessment and Market Forecasts to 2016 |
Jul 2010 | £1,265 | 63% |
| Carolinas Healthcare System - Developmental Therapeutics Review Q4 2010 |
Dec 2010 | £315 | 62% |
| Bronchopulmonary Dysplasia - Pipeline Review H2 2011 |
Aug 2011 | £315 | 61% |
| Congenital Heart Disease - Pipeline Review Q2 2011 |
May 2011 | £315 | 60% |
| Ischemia - Pipeline Review H1 2012 |
Jan 2012 | £325 | 58% |
| Novel Targets in Drug Discovery | Apr 2004 | £595 | 58% |
| Pulmonary Arterial Hypertension (PAH) Pipeline Assessment and Market Forecasts to 2016 |
Jun 2010 | £1,265 | 57% |
| Transdermal Drug Delivery Technologies, Markets and Companies |
Jan 2012 | £1,945 | 56% |
| Osteoarthritis (OA) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Nov 2011 | £2,215 | 56% |
| Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016 | Feb 2010 | £1,265 | 54% |
| Diabetic Foot Ulcers - Pipeline Review H2 2011 |
Oct 2011 | £315 | 54% |
| Cell therapy (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,560 | 52% |
| Gene Therapy (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,240 | 51% |
| Drug Delivery in Cancer (2 pt) Technologies, Markets and Companies |
Jan 2012 | £2,590 | 43% |
